July 2024 – Page 12 – Goldea Capital

HUTCHMED Reports 2024 Interim Results and Provides Business Updates

Written by Customer Service on July 31, 2024. Posted in Earnings Releases And Operating Results.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 31, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:HCM; HKEX:13) today reports its financial results for the six months ended June 30, 2024 and provides updates on key clinical and commercial developments. HUTCHMED to host results webcasts today at 8:00 a.m. EDT / 1:00 p.m. BST / 8:00 p.m. HKT in English, and at 8:30 a.m. HKT in Chinese (Putonghua) on Thursday, August 1, 2024. After registration, investors may access the live webcast via HUTCHMED’s website at www.hutch-med.com/event. All amounts are expressed in US dollars unless otherwise stated. Continued revenue momentum with substantial cash balance to support growth Reiterate full year 2024 guidance for Oncology/Immunology consolidated revenue of $300 to $400 million,...

Codere Online Reports Financial Results for the Second Quarter 2024

Written by Customer Service on July 31, 2024. Posted in Earnings Releases And Operating Results.

Total revenue was €51.7 mm in Q2 2024, while net gaming revenue1 was €54.4 mm in the period, 39% above Q1 2023. Mexico revenue was €25.3 mm in Q2 2024, while net gaming revenue was €28.2 mm in the period, 57% above Q2 2023. Spain revenue (and net gaming revenue) reached €21.8 mm in Q2 2024, 25% above Q2 2023. Net income excluding the non-cash variation in fair value of public warrants2 was €5.5 mm in H1 2024 versus a net loss of €0.7 mm in H1 2023. Total cash position of €40.5 mm as of June 30, 2024. Increasing full year 2024 net gaming revenue outlook to €205 – 215 mm and Adj. EBITDA3 outlook to positive €2.5 – 7.5 mm. Madrid, Spain and Tel Aviv, Israel, July 31, 2024 – (GLOBE NEWSWIRE) Codere Online (Nasdaq: CDRO / CDROW, the “Company”), a leading online gaming operator in Spain and Latin America, has released its preliminary...

Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance

Written by Customer Service on July 31, 2024. Posted in Earnings Releases And Operating Results.

For an accessible version of this Press Release, please visit www.tevapharm.com Q2 2024 revenues of $4.2 billion reflecting an increase of 7% in U.S. dollars or 11% in local currency terms compared to Q2 2023. Generics business grows across all regions – increased in local currency terms by 16% in the U.S., 8% in Europe and 22% in International Markets, compared to Q2 2023. AUSTEDO – continued growth, U.S. revenue of $407 million in Q2 2024, an increase of 32% compared to Q2 2023; raising 2024 revenue outlook to ~$1.6 billion. AJOVY® – global revenues of $115 million in Q2 2024, an increase of 12% in local currency terms compared to Q2 2023. Announced acceleration of development timeline for duvakitug (Anti-TL1A) – top-line results now expected in Q4 2024, with full data expected next year. Announced positive Phase 3 efficacy results...

Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation

Written by Customer Service on July 31, 2024. Posted in Public Companies.

TARRYTOWN, N.Y., July 31, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 12th annual Regeneron Prize for Creative Innovation (the Regeneron Prize), an award that recognizes, celebrates and rewards outstanding talent and creativity from early-career scientists in biomedical research. Each year, Regeneron asks leading research universities across the United States to nominate their top graduate students and postdoctoral fellows, who are then invited to conceptualize and propose “dream projects” within the realm of biomedical science. The finalists present their proposals to a selection committee comprised of Regeneron’s leading scientists who evaluate the projects based on scientific merit, creativity and originality. This year’s winners are Christopher Giuliano...

LeddarTech Unveils the Future of ADAS With the European Launch of the LeddarNavigator Demo Car and Road Show

Written by Customer Service on July 31, 2024. Posted in Public Companies.

QUEBEC CITY, Canada, July 31, 2024 (GLOBE NEWSWIRE) — LeddarTech® Holdings Inc. (“LeddarTech”) (Nasdaq: LDTC), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology, LeddarVision™, for ADAS, AD and parking applications, is proud to present the high-performance LeddarNavigator. This demo car will showcase the next level in ADAS technology to automotive OEMs and Tier 1s during its tour across Europe beginning July 25, 2024 and ending at Autosens Europe in Barcelona, Spain, on October 10, 2024. The LeddarNavigator is equipped with the LeddarVision AI-based low-level sensor fusion and perception family of automotive software products. These extend sensor performance beyond what is typically achieved with object-level fusion and address the known cost...

Quipt Home Medical Corp. to Announce Fiscal Third Quarter 2024 Financial Results on August 14, 2024

Written by Customer Service on July 31, 2024. Posted in Public Companies.

CINCINNATI, July 31, 2024 (GLOBE NEWSWIRE) — Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal third quarter 2024 financial results on Wednesday, August 14, 2024, after market close. Gregory Crawford, Chief Executive Officer, and Hardik Mehta, Chief Financial Officer, will host a conference call for the investment community on Thursday, August 15, 2024, at 10:00 a.m. (ET). The call-in numbers for participants are: Canada/US Toll Free: 1 (844) 763 8274 International: 1 (647) 484 8814 A live webcast of the call will be accessible via the investor section of the Company’s website through the following link: www.quipthomemedical.com. ABOUT QUIPT HOME MEDICAL The Company provides in-home...

DBG Announces Successful Launch of its New DTC Strategy DSTLD Orders Rise 144% Since June Launch

Written by Customer Service on July 31, 2024. Posted in Public Companies.

Austin, TX, July 31, 2024 (GLOBE NEWSWIRE) — Digital Brands Group, Inc. (“DBG”) (NASDAQ: DBGI), a curated collection of luxury lifestyle, digital-first brands, today announces a successful launch of its new DTC strategy. The new strategy focuses on driving significant customer value through discounts offered to customers who bundle multiple units in one purchase, which is referred to as “Build Your Own Bundle” or BYOB. Since launching this new BYOB strategy in mid-June, DSTLD has experienced a 144% increase in its orders. Additionally, DSTLD orders are up 400%+ when there are dedicated email campaigns featuring this BYOB promotion. “Given the current inflationary environment, as well as the success of companies that have focused on creating discounted bundles, we tested this BYOB strategy with DSTLD. After seeing the terrific results,...

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

Written by Customer Service on July 31, 2024. Posted in Public Companies.

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced today that it has regained compliance with the Nasdaq Capital Market’s market value of listed securities (“MVLS”) requirement. On July 23, 2024, MiNK received notice from NASDAQ confirming that the Company has satisfied the MVLS requirement as set forth in Nasdaq Listing Rule 5550(b)(2). Accordingly, the Company now satisfies the MVLS requirement for continued listing on the NASDAQ Capital Market and the matter is now closed. About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company...

SAB BIO Appoints Lucy To as Chief Financial Officer

Written by Customer Service on July 31, 2024. Posted in Public Companies.

MIAMI, July 31, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Lucy To has been named Chief Financial Officer effective August 12, 2024. Ms. To brings over 18 years of investment banking and strategic operational expertise to SAB and will lead corporate finance, corporate strategy and approach to broader strategic business relationships at the company. “Lucy’s proven track record and experience will prove invaluable to SAB as we continue to deliver on our upcoming milestones for SAB-142,” notes Samuel J. Reich, Chairman and CEO of SAB. “I’m thrilled to welcome her...

GOe3 Unveils AI Designed to Protect User Identity and Empower Individuals

Written by Customer Service on July 31, 2024. Posted in Public Companies.

PARSIPPANY, New Jersey, July 31, 2024 (GLOBE NEWSWIRE) — Global Technologies, Ltd. (OTC Pink: GTLL) (the “Company”) is pleased to announce that its subsidiary, GOe3, LLC, has launched a revolutionary Artificial Intelligence (AI) system designed from the ground up to protect user identities while simultaneously delivering an authentic user experience to the marketplace. The new AI system offers the following key features: Complete Anonymity: The AI system ensures complete anonymity for users, always protecting their identities and personal information. Income for User Data: In a first-of-its-kind initiative, the AI system provides users with income for their data. This innovative approach acknowledges the value of user data and empowers individuals to benefit from it. AI Assistant: The AI system also functions as a personal assistant,...

Month: July 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice